Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans

174Citations
Citations of this article
166Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Lithium (Li+) has been used to treat mood affect disorders, including bipolar, for decades. This drug is neuroprotective and has several identified molecular targets. However, it has a narrow therapeutic range and the one or more underlying mechanisms of its therapeutic action are not understood. Here we describe a pharmacogenetic study of Li+ in the nematode Caenorhabditis elegans. Exposure to Li+ at clinically relevant concentrations throughout adulthood increases survival during normal aging (up to 46% median increase). Longevity is extended via a novel mechanism with altered expression of genes encoding nucleosome-associated functions. Li + treatment results in reduced expression of the worm ortholog of LSD-1 (T08D10.2), a histone demethylase; knockdown by RNA interference of T08D10.2 is sufficient to extend longevity (∼25% median increase), suggesting Li+ regulates survival by modulating histone methylation and chromatin structure. © 2008 by The American Society for Biochemistry and Molecular Biology, Inc.

Cite

CITATION STYLE

APA

McColl, G., Killilea, D. W., Hubbard, A. E., Vantipalli, M. C., Melov, S., & Lithgow, G. J. (2008). Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. Journal of Biological Chemistry, 283(1), 350–357. https://doi.org/10.1074/jbc.M705028200

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free